Causality between autoimmune diseases and breast cancer: a two-sample Mendelian randomization study in a European population-Reference-Cited by-同舟云学术

Causality between autoimmune diseases and breast cancer: a two-sample Mendelian randomization study in a European population

Published:2024-09-01 Issue:1 Volume:15 Page:
ISSN:2730-6011
Container-title:Discover Oncology
language:en
Short-container-title:Discov Onc

Author:

Zhang Hengheng,Shen Guoshuang,Yang Ping,Wu Meijie,Li Jinming,Li Zitao,Zhao Fuxing,Liang Hongxia,Da Mengting,Wang Ronghua,Zhang Chengrong,Zhao Jiuda,Zhao Yi

Funder

Central Government Guiding Local Scientific and Technological Development Funds for Qinghai Province in China

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s12672-024-01269-6.pdf

Reference51 articles.

1. Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, Siegel RL. Breast cancer statistics, 2022. CA A Cancer J Clin. 2022;72(6):524–41. https://doi.org/10.3322/caac.21754.

2. Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, Soerjomataram I. Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast. 2022;66:15–23. https://doi.org/10.1016/j.breast.2022.08.010.

3. Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LAG, Cronin KA. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. JNCI J Natl Cancer Inst. 2014. https://doi.org/10.1093/jnci/dju055.

4. Priedigkeit N, Hartmaier RJ, Chen Y, Vareslija D, Basudan A, Watters RJ, Lee AV. Intrinsic subtype switching and acquired ERBB2/HER2 amplifications and mutations in breast cancer brain metastases. JAMA Oncol. 2017;3(5):666–71. https://doi.org/10.1001/jamaoncol.2016.5630.

5. Garcia-Recio S, Thennavan A, East MP, Parker JS, Cejalvo JM, Garay JP, Perou CM. FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease. J Clin Investig. 2020;130(9):4871–87. https://doi.org/10.1172/JCI130323.